Unveiling the relative efficacy, safety and tolerability of prophylactic medications for migraine: pairwise and network-meta analysis

He, Aijie; Song, Dehua; Zhang, Lei; Li, Chen

doi:10.1186/s10194-017-0720-7

Table 1 Studies identified for the NMA with interventions and outcomes evaluated

From: Unveiling the relative efficacy, safety and tolerability of prophylactic medications for migraine: pairwise and network-meta analysis

Author, Year	Center	Design	Blind	Mechanism of action	Intervention	Size	Male (%)	Follow-up	Age	Clinical outcomes
Silberstein et al., 2013 [42]	Multi	RCT	Double	Anticonvulsants	Gabapentin vs. Placebo	523	21	20w	39.4	①③④⑤⑥⑦⑧⑨
Afshari et al., 2012 [41]	Mono	RCT	Double	Anticonvulsants	Topiramate vs. Valproate	56	21	12w	32.1	②④⑤⑥⑧⑨
Lipton et al., 2011 [40]	Multi	RCT	Double	Anticonvulsants	Topiramate vs. Placebo	330	13	26w	39.6	①④⑤⑥⑦⑧⑨
Holroyd et al., 2010 [39]	Multi	RCT	Double	β blocker	Propranolol vs. Placebo	106	21	16m	38.2	①⑧⑨
Dodick et al., 2009 [38]	Multi	RCT	Double	Anticonvulsants	Topiramate vs. Amitriptyline	346	15	26w	38.8	①④⑤⑥⑦⑧⑨
Ashtari et al., 2008 [37]	Mono	RCT	Double	Anticonvulsants	Topiramate vs. Propranolol	62	21	8w	30.5	②⑥⑦⑧⑨
Silberstein et al., 2007 [36]	Multi	RCT	Double	Anticonvulsants	Topiramate vs. Placebo	306	15	126d	38.2	①④⑤⑥⑦⑧⑨
Gupta et al., 2007 [35]	Mono	Crossover	Double	Anticonvulsants	Topiramate vs. Placebo	60	22	20w	29.4	①④⑧⑨
Diener et al., 2007 [33, 34]	Multi	RCT	Double	Anticonvulsants	Topiramate vs. Placebo	59	26	16w	46.2	①④⑤⑥⑦⑧
Diener et al., 2007 [33, 34]	Multi	RCT	Double	Anticonvulsants	Topiramate vs. Placebo	514	13	6m	39.8	①④⑤⑦⑧
Tommaso et al., 2007 [32]	Mono	RCT	Double	Anticonvulsants	Topiramate vs. Placebo	30	22	1d	37.9	⑨
Silberstein et al., 2006 [31]	Multi	RCT	Double	Anticonvulsants	Topiramate vs. Placebo	211	14	12w	40.5	④
Shaygannejad et al., 2006 [30]	Mono	Crossover	Double	Anticonvulsants	Topiramate vs. Valproate	64	57	24w	34.1	②⑥
Brandes et al., 2006 [29]	Multi	RCT	Double	Anticonvulsants	Topiramate vs. Placebo	468	13	13m	38.8	②⑧⑨
Silberstein et al., 2004 [28]	Multi	RCT	Double	Anticonvulsants	Topiramate vs. Placebo	469	11	26w	40.4	①②③⑤⑥⑧⑨
Mei et al., 2004 [27]	Mono	RCT	Double	Anticonvulsants	Topiramate vs. Placebo	115	46	16w	39.2	②③④⑥⑧⑨
Diener et al., 2004 [26]	Multi	RCT	Double	Anticonvulsants	Topiramate vs. Propranolol	568	20	1y	41.0	①②④⑤⑥⑧⑨
Brandes et al., 2004 [25]	Multi	RCT	Double	Anticonvulsants	Topiramate vs. Placebo	483	13	26w	38.8	⑤⑧⑨
Freitag et al., 2002 [24]	Multi	RCT	Double	Anticonvulsants	Divalproex vs. Placebo	237	21	12w	40.5	①②③④⑤⑥⑧⑨
Storey et al., 2001 [23]	Mono	RCT	Double	Anticonvulsants	Topiramate vs. Placebo	40	25	12w	38.2	②③⑧⑨
Mathew et al., 2001 [22]	Multi	RCT	Double	Anticonvulsants	Gabapentin vs. Placebo	143	17	16w	39.4	②③④⑥⑦⑧⑨
Klapper, 1997 [21]	Multi	RCT	Single	Anticonvulsants	Divalproex vs. Placebo	176	12	12w	40.5	③④⑤⑥⑧⑨
Kaniecki, 1997 [20]	Mono	RCT	Single	Anticonvulsants	Divalproex vs. Propranolol	37	19	12w	40.1	④⑤⑦⑨
Diener et al, 1996 [19]	Multi	RCT	Double	β blocker	Propranolol vs. Placebo	133	22	12w	39.0	③⑧⑨
Bendtsen et al., 1996 [18]	Mono	Crossover	Double	Antidepressive	Amitriptyline vs. Placebo	40	38	32w	40.0	④⑤⑦⑨
Mathew et al., 1995 [17]	Multi	RCT	Double	Anticonvulsants	Divalproex vs. Placebo	107	20	12w	46.0	①③⑤⑥⑧⑨
Hering and Kuritzky, 1992 [16]	Mono	Crossover	Double	Anticonvulsants	Valproate vs. Placebo	32	21	16w	34.0	⑤⑦⑨
Pradalier et al., 1989 [15]	Multi	RCT	Double	β blocker	Propranolol vs. Placebo	74	24	16w	37.4	②⑤⑦⑧⑨
Mikkelsen et al., 1986 [14]	Mono	Crossover	Double	β blocker	Propranolol vs. Placebo	31	16	12w	38.0	④⑧⑨
Sadeghian andMotiei-Langroudi, 2015 [45]	Mono	RCT	Double	Anticonvulsants	Valproate vs. Placebo	58	27	6m	35.3	③④⑨
Sarchielli et al., 2014 [44]	Multi	RCT	Double	Anticonvulsants	Valproate vs. Placebo	88	21	6m	42.0	④⑤⑦⑧⑨
Nofal et al., 2014 [43]	Moni	RCT	Double	Anticonvulsants	Gabapentin vs. Placebo	86	0	4d	30.9	⑤⑦

Outcomes: ① monthly migraine headache days; ② headache frequency; ③ ≥50% reduction in migraine headache attacks; ④ all-adverse events; ⑤ nausea; ⑥ somnolence; ⑦ dizziness; ⑧ withdrawal; ⑨ withdrawal due to adverse events

Back to article page

ISSN: 1129-2377

Contact us

Submission enquiries: journalsubmissions@springernature.com

The Journal of Headache and Pain

Contact us